Literature DB >> 25461735

Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects.

Cinthia E Jannes1, Raul D Santos2, Pãmela R de Souza Silva3, Luciana Turolla3, Ana C M Gagliardi3, Julia D C Marsiglia3, Ana P Chacra2, Marcio H Miname2, Viviane Z Rocha2, Wilson Salgado Filho2, Jose E Krieger3, Alexandre C Pereira3.   

Abstract

BACKGROUND: There is little knowledge about familial hypercholesterolemia in Brazil. This study presents the first results of genetic cascade screening performed in the city of Sao Paulo.
MATERIAL AND METHODS: Two-hundred and forty-eight suspected index cases were initially included. DNA was extracted from peripheral blood and the complete coding sequence of low-density lipoprotein receptor, exon 7 of proprotein convertase subtilisin/kexin type 9 gene and part of exon 26 of apolipoprotein B genes were sequenced. Multiplex Ligation-dependent Probe Amplification was performed on cases where a causal mutation was not identified through sequencing. After the identification of a causal mutation screening in first-degree relatives was pursued.
RESULTS: From 248 index cases, a mutation was found in 125 individuals (50.4%). 394 relatives were included in the cascade screening program and a mutation was identified in 59.4%. Seventy different causal mutations in the low-density lipoprotein receptor gene (97.2%) and 2 in the apolipoprotein B gene (2.8%) were found. No mutations were encountered in the proprotein convertase subtilisin/kexin type 9 gene. Mutations in exons 14 and 4 were the most prevalent and, 10 cases of true homozygotes (8 index cases and 2 relatives) and 1 compound heterozygote were identified. The most frequent mutation found was of Lebanese origin, the p.(Cys681*) mutation in exon 14 (8.5%).
CONCLUSION: Genetic familial hypercholesterolemia cascade screening is feasible in Brazil and leads to identification of a mutation in approximately half of the index cases with higher rates of success in their relatives.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apolipoprotein B; Cascade screening; Familial hypercholesterolemia; Index patient; Low density lipoprotein receptor; Mutations

Mesh:

Substances:

Year:  2014        PMID: 25461735     DOI: 10.1016/j.atherosclerosis.2014.11.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  17 in total

1.  Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families.

Authors:  Xue Wu; Jing Pang; Xumin Wang; Jie Peng; Yan Chen; Shilong Wang; Gerald F Watts; Jie Lin
Journal:  Clin Cardiol       Date:  2017-11-23       Impact factor: 2.882

Review 2.  The panorama of familial hypercholesterolemia in Latin America: a systematic review.

Authors:  Roopa Mehta; Rafael Zubirán; Alexandro J Martagón; Alejandra Vazquez-Cárdenas; Yayoi Segura-Kato; María Teresa Tusié-Luna; Carlos A Aguilar-Salinas
Journal:  J Lipid Res       Date:  2016-10-24       Impact factor: 5.922

Review 3.  Management of patients with familial hypercholesterolaemia.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

4.  Cardiovascular Statistics - Brazil 2021.

Authors:  Gláucia Maria Moraes de Oliveira; Luisa Campos Caldeira Brant; Carisi Anne Polanczyk; Deborah Carvalho Malta; Andreia Biolo; Bruno Ramos Nascimento; Maria de Fatima Marinho de Souza; Andrea Rocha De Lorenzo; Antonio Aurélio de Paiva Fagundes Júnior; Beatriz D Schaan; Fábio Morato de Castilho; Fernando Henpin Yue Cesena; Gabriel Porto Soares; Gesner Francisco Xavier Junior; Jose Augusto Soares Barreto Filho; Luiz Guilherme Passaglia; Marcelo Martins Pinto Filho; M Julia Machline-Carrion; Marcio Sommer Bittencourt; Octavio M Pontes Neto; Paolo Blanco Villela; Renato Azeredo Teixeira; Roney Orismar Sampaio; Thomaz A Gaziano; Pablo Perel; Gregory A Roth; Antonio Luiz Pinho Ribeiro
Journal:  Arq Bras Cardiol       Date:  2022-01       Impact factor: 2.000

5.  Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2022-08-23

6.  Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.

Authors:  Abhimanyu Garg; Sergio Fazio; P Barton Duell; Alexis Baass; Chandrasekhar Udata; Tenshang Joh; Tom Riel; Marina Sirota; Danielle Dettling; Hong Liang; Pamela D Garzone; Barry Gumbiner; Hong Wan
Journal:  J Endocr Soc       Date:  2019-11-29

7.  Targeted Screening of Familial Hypercholesterolemia in 11 Small Brazilian Cities: An Effective Approach to Detect Clusters of Affected Individuals.

Authors:  Maria Cristina Oliveira Izar; Francisco A H Fonseca
Journal:  Arq Bras Cardiol       Date:  2022-04       Impact factor: 2.000

Review 8.  The genetics and screening of familial hypercholesterolaemia.

Authors:  Raymond Henderson; Maurice O'Kane; Victoria McGilligan; Steven Watterson
Journal:  J Biomed Sci       Date:  2016-04-16       Impact factor: 8.410

9.  Mutation detection in Chinese patients with familial hypercholesterolemia.

Authors:  Ran Du; Liang-Liang Fan; Min-Jie Lin; Zhi-Jian He; Hao Huang; Ya-Qin Chen; Jing-Jing Li; Kun Xia; Shui-Ping Zhao; Rong Xiang
Journal:  Springerplus       Date:  2016-12-12

10.  Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.

Authors:  Joana Rita Chora; Ana Margarida Medeiros; Ana Catarina Alves; Mafalda Bourbon
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.